Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia.
Preeclampsia is a leading cause of maternal and fetal morbidity and mortality worldwide. It occurs in two phases: abnormal implantation of the placenta leads to impaired placental blood flow, which in turn induces the release of a critical placental substance into the maternal circulation (1). Clinical onset usually occurs in the third trimester of pregnancy, long after initiation of the underlying process.
Recently, Maynard et al. (2) compared the gene expression profile in placental tissue from women with and without preeclampsia and identified soluble Flt1 (sFlt1), a vascular endothelial growth factor receptor, as a molecule of particular pathophysiologic interest. It is now suspected that trophoblastic injury markedly enhances placental sFlt1 production, antagonizing the endothelial protective role of vascular endothelial growth factor and/or placental growth factor and eventually leading to clinical preeclampsia (2, 3). A recent study pointed out that, compared with women with a retrospective diagnosis of normal pregnancy (i.e., without hypertension), preeclamptic women had increased serum sFlt1 several weeks before the onset of clinical disease, suggesting that this protein might be used as a predictive marker for preeclampsia (4).
We measured sFlt1 concentrations in serial serum samples from pregnant women with normal or pathologic pregnancy outcomes, including patients with gestational or chronic hypertension but without preeclampsia. The study population consisted of 23 pregnant women followed prospectively in our Obstetric Gynecology Department between 1996 and 2001. The study was approved by our Institutional Review Board. Inclusion criteria were as follows: available serial serum samples collected through pregnancy (stored at -20[degrees]C) and a final diagnosis of preeclampsia, isolated hypertension, or normal pregnancy. Preeclampsia was defined as the onset, after 20 weeks of gestation, of both hypertension (>140/90 mmHg) and proteinuria (>300 mg/L), or proteinuria (>300 mg/L) in a patient with preconceptional hypertension. Gestational hypertension was defined as hypertension occurring after 20 weeks of gestation, without proteinuria. Chronic hypertension was defined as preconceptional treated hypertension. Patients with gestational and chronic hypertension were pooled for analysis.
Serum sFlt1 concentrations were measured by an immunoassay (Quantikine; R&D Systems); the person (A.H.) who performed the assay was blinded to the clinical diagnoses of the patients. All measurements were made in duplicate on 1:10 dilutions of the sera. Comparisons between multiple groups were made with the nonparametric Mann-Whitney test, and correlations between data were analyzed by the Spearman test. A P value <0.05 was considered statistically significant.
We analyzed 93 serum samples, from 23 patients, collected at various stages of pregnancy. Eight women had preeclampsia (one of whom had chronic hypertension), either mild (n = 7) or severe (n = 1). Intrauterine growth retardation was present in one case. Six women had isolated hypertension (four with chronic hypertension and two with gestational hypertension), and nine women had normal pregnancies.
[FIGURE 1 OMITTED]
Mean (SD) serum sFlt1 concentrations at delivery were higher in women with preeclampsia [5332 (3187) ng/L] than in those with normal pregnancies [1483 (1148) ng/L; P = 0.027] or isolated hypertension [1607 (1059) ng/L; P = 0.039 vs preeclampsia; P = 0.724 vs normal pregnancy]. As shown in Fig. 1, sFlt1 concentrations increased gradually throughout pregnancy in women with preeclampsia. No significant difference in sFlt1 concentrations was observed among the three groups before 20 weeks of gestation. In contrast, mean (SD) serum sFlt1 was significantly higher between 25 and 28 weeks of gestation in women with preeclampsia [2779 (1837) ng/L] than in women with normal pregnancies [552 (246) ng/L; P = 0.028] or isolated hypertension [544 (359) ng/L; P = 0.0526 vs preeclampsia; P = 0.732 vs normal pregnancy]. No specific pattern was observed in the group with isolated hypertension.
A sFlt1 cutoff value of 957 ng/L between 25 and 28 weeks of gestation yielded a specificity of 100% and sensitivity of 80% (95% confidence interval, 28.8-96.7%), respectively, for subsequent clinical onset of preeclampsia. Only one of the eight women who went on to develop preeclampsia (at 34 weeks of gestation) had sFlt1 values within the reference interval. This woman had abruptio placenta at delivery (36 weeks of gestation). In the remaining seven patients, the sFlt1 assay would have predicted preeclampsia a mean of 11.2 weeks (range, 6.5-16.5 weeks) before clinical onset. No significant difference was observed in mean (SD) serum creatinine concentrations ([micro]mol/L) among the three groups [normal pregnancy, 52.5 (8.9); preeclampsia, 57.0 (14.9); isolated hypertension, 54 (16.6)].
Our findings confirm that the maternal serum sFlt1 concentration is markedly increased at delivery in women with preeclampsia and is measurably increased long before clinical onset (minimum of 6.5 weeks before onset). We emphasize the surprising lack of negative predictive value of a sFlt1 concentration within reference values in pregnancies complicated by abruptio placenta. We believe that measurement of sFlt1 could permit early management of at-risk women and could also help to identify women at risk of developing preeclampsia among patients presenting with gestational or chronic hypertension.
(1.) Roberts JIM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357: 53-6.
(2.) Maynard SE, Min J-Y, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-58.
(3.) Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605-8.
(4.) Richard JL., Maynard SE, Qian C, Lim KH, England U, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
Alexandre Hertig  *
Nadia Berkane 
Guillaume Lefevre 
Karine Toumi 
Hans-Peter Marti 
Jacqueline Capeau 
Serge Uzan 
Eric Rondeau [1,4]
 Institut National de la Sante et de la Recherche Medicale (INSERM) U489
 Department of Gynecology and Obstetrics
 Department of Biochemistry and
 Department of Nephrology Hopital Tenon Paris, France
* Address correspondence to this author at: Hopital Tenon, 4 rue de la Chine, NA 75020 Paris, France. Fax 33-1-43645448; e-mail alexandre.hertig@tnn. ap-hop-paris.fr.
|Printer friendly Cite/link Email Feedback|
|Author:||Hertig, Alexandre; Berkane, Nadia; Lefevre, Guillaume; Toumi, Karine; Marti, Hans-Peter; Capeau, Jac|
|Article Type:||Letter to the editor|
|Date:||Sep 1, 2004|
|Previous Article:||Deuterium dilution: the time course of [sup.2]H enrichment in saliva, urine, and serum.|
|Next Article:||3-deazaadenosine, a stabilizer of whole-blood homocysteine content, does not interfere with the single-enzyme homocysteine assay while totally...|